Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Key Inclusion Criteria: * Subject is at least 4 years of age at Screening * Subject has a documented genetic mutation consistent with EBS. Gene mutations acceptable for inclusion are as follows: KRT5, KRT14, PLEC1, TGM5, PKP1, DSP, FERMT1, EXPH5, DST, KLHL24. * Subject has an Assessment Area of EBS lesions to be treated, that is ≥2% body surface area (BSA) and the EBS lesions are in one or both of the following body areas: * Localized: plantar and/or palmar areas * Generalized: arms, legs, torso, hands and feet * Subject's EBS lesions in the Assessment Area have an Investigator's Global Assessment (IGA) score of ≥3 * Subject/caregiver agrees to not use any topical therapies other than the study medication that might influence the status of the EBS lesions during the duration of the study * Subject is non-pregnant as confirmed by a negative urine pregnancy screen, non-lactating and is not planning for pregnancy during the study period * If the subject is a woman of childbearing potential, agrees to use an approved effective method of birth control * Subject is in good general health and free of any known disease state or physical condition which might impair evaluation of the EBS lesions or which exposes the subject to an unacceptable risk by study participation Key Exclusion Criteria: * Subject has EBS lesions to be treated that are infected * Subject has used any diacerein containing product within 6 months prior to Screening * Subject has used systemic immunotherapy…